Introduction: With an annual incidence of 5/100,000, meningioma is the most frequent
primary tumor of the central nervous system. Risk factors are radiotherapy and hormone …

Atypical meningiomas (AMs) and malignant meningiomas (MMs) are tumors with a lower
incidence and poorer prognosis than benign meningiomas. The role of radiotherapy as an …

Purpose The therapeutic strategy for non-benign meningiomas is controversial. The
objective of this study was to prospectively investigate the impact of high dose radiation …

Abstract Background Because World Health Organization (WHO) grades II and III
meningiomas are relatively uncommon, there is limited literature on the descriptive …

Meningiomas represent one of the largest subgroups of intracranial tumors. They are
generally benign, but may show a histological progression to malignancy. Grades II and III …

Abstract BACKGROUND: Grade II and III meningiomas have higher rates of tumor
recurrence than grade I meningiomas after surgery and/or external irradiation. As the utility …

There are no effective medical treatments for WHO grade III (anaplastic) meningioma.
Patients with this high-grade malignancy have a median survival of less than two years …

Object Atypical (WHO Grade II) meningiomas comprise a heterogeneous group of tumors,
with histopathology delineated under the guidance of the WHO and a spectrum of clinical …

Atypical meningioma has an aggressive clinical course. Distinguishing atypical from benign
meningioma preoperatively could affect surgical planning and improve treatment outcomes …

Although the majority of meningiomas are slow-growing and benign, atypical and anaplastic
meningiomas behave aggressively with a penchant for recurrence. Standard of care …